Cspc Megalith Biopharmaceutical Co.,ltd.

This study tests a new mRNA vaccine (SYS6017) to prevent shingles, a painful rash caused by the chickenpox virus reactivating. About 800 healthy adults aged 40 and older will receive either the new vaccine, a placebo, or an existing shingles vaccine. Researchers will check how we…

This phase 3 trial tests a new drug called SYS6002 against standard chemotherapy for people with advanced bladder cancer that has not responded to platinum chemo and immunotherapy. About 406 adults aged 18-75 will be randomly assigned to receive either SYS6002 or a chemo chosen b…

This study tests a new drug called SYS6010 against a standard chemotherapy (docetaxel) in people with a specific type of advanced lung cancer (non-squamous non-small cell) that no longer responds to standard treatments. About 506 adults will be randomly assigned to receive either…

This study tests a new drug combination (SYS6023 plus other treatments) in people with advanced breast cancer that cannot be removed by surgery or has spread. The goal is to find the best dose, check safety, and see if the combination shrinks tumors. About 114 adults with a speci…

This study tests whether a new combination of drugs (SYS6010 and SG001), with or without standard chemotherapy, can shrink tumors and help people with advanced esophageal cancer live longer. About 737 adults who have not had prior treatment for their advanced cancer will take par…

This study tests whether adding a new drug (SYS6010) to the standard targeted therapy (osimertinib) before surgery helps shrink tumors more effectively in people with a specific type of lung cancer (EGFR-mutant non-small cell lung cancer). About 120 adults with stage II to IIIB c…

This study tests a new drug called SYS6010 against standard chemotherapy for people with advanced esophageal cancer that has worsened after at least one prior treatment. About 436 participants will be randomly assigned to receive either SYS6010 or a standard chemo drug chosen by …

This study tests a new drug called SYS6010 against standard chemotherapy in people with advanced breast cancer that has not responded to previous treatments. The cancer must be HER2-negative and EGFR-positive. About 400 participants will be randomly assigned to receive either SYS…

This study tests whether adding a new drug (SYS6010) to the standard treatment osimertinib can help people with a certain type of advanced lung cancer (EGFR-mutant NSCLC) live longer without their cancer getting worse. About 680 adults aged 18 to 75 will be randomly assigned to r…

This early-phase study tests a new drug called SYS6051 in about 114 adults with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants must be 18 or older,…

This study compares a new drug called SYS6002 to an existing drug (PADCEV) in people with advanced bladder cancer that has worsened after chemotherapy and immunotherapy. About 100 adults aged 18-80 will be randomly assigned to one of the two treatments. The main goal is to check …

This phase 3 trial tests a new drug called SYS6002 against standard chemotherapy for people with advanced cervical cancer that has returned or spread after prior treatments. About 412 adults aged 18-75 will be randomly assigned to receive either SYS6002 or a chemotherapy chosen b…